Disproportional response: a small company's current business is visibly outgrowing its own size
The model's full reasoning — Q2 2022 call → NOWe need to determine if management conveys that the business is currently outgrowing the company's size, i.e., that what is happening now is disproportionately large relative to the company's smallness. Look for statements about current activity, demand, commitments, volumes, etc., that are large relative to the company's current scale. In the transcript, management discusses the grocer issue, revenue impacts, and growth in other areas. They mention that pharma manufacturer solutions revenue grew 102% year-over-year, but that's growth, not necessarily disproportion. They also mention that they have penetrated less than 1% of a $30 billion TAM, but that's a market size statistic, not current activity. They talk about new user counts being close to prior levels, but that's not a disproportion. They mention that the grocer issue caused a $30 million revenue hit, which is significant relative to their revenue, but that's a loss, not growth. They also mention that they are taking actions to improve cost structure, but that's not about scale. The key question: does management convey that the company is small and that what is happening now is disproportionately large? For example, they might say that a single contract or partnership could rival the company's size, or that they are handling volumes that would have been out of reach until now. I don't see such statements. They talk about growth in pharma manufacturer solutions, but they don't say it's large relative to the company's size. They mention that they have a large TAM, but that's generic. They also mention that they are expanding into new areas like vitaCare, but that's an acquisition, not necessarily a disproportion. The transcript is mostly about the grocer issue and its impact, and about guidance. There is no explicit statement that the company is small and that current business is disproportionately large. They do say that they are a leading brand, but that doesn't imply disproportion. Thus, the answer is NO.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| KOPN | Kopin Corporation | Q4 2023 | 2024-03-14 | C+ |
| TMCI | Treace Medical Concepts, Inc. | Q2 2022 | 2022-08-13 | B+ |
| VNRX | VolitionRx Limited | Q1 2022 | 2022-05-12 | F |
| FLUX | Flux Power Holdings, Inc. | Q2 2022 | 2022-02-10 | D |
VNRX · Q1 2022 → YESThe question is: Does management convey that the business the company is doing RIGHT NOW is visibly outgrowing the company's own current size and setup? That current activity, demand, or commitments a...YES The transcript shows management explicitly describing the Heska deal (already signed and with $10M upfront received) as a long-term, multi-year commitment that will generate ongoing kit/component revenue "significantly greater" than the $28M milestones, with "millions of tests" expected each year — all while repeatedly noting the company is "not a big company" and that this is "the beginning of our commercial journey" after 12 years of R&D. They contrast this with their tiny current revenue ($114k) and cash position, framing the new activity as disproportionately large relative to their size.
TMCI · Q2 2022 → YESThe question is: Does management convey that the business the company is doing RIGHT NOW is visibly outgrowing the company's own current size and setup? That current activity, demand, or commitments a...YES Management explicitly describes the business as outgrowing its current setup in present-tense terms: they are “once again in the process of relocating to a larger headquarters facility” to meet “increased requirements” for training, R&D, warehousing, and infrastructure; the direct sales force has grown 52% to 123 quota-carrying reps and is already trending above the year-end 70% direct mix goal; surgeon penetration has reached 20% of the estimated 10,000 U.S. foot-and-ankle surgeons while procedure penetration is 4.6% of the 450,000 annual U.S.
KOPN · Q4 2023 → YESThe question is: Does management convey that the business the company is doing RIGHT NOW is visibly outgrowing the company's own current size and setup? That current activity, demand, or commitments a...YES The transcript shows management describing current activity (a $55 million backlog, a $20.5 million new order, follow-on orders, and tripled weapon-site volume expected in 2024) as large relative to the company’s still-small size and setup. They explicitly note the backlog is a “record level 10 years,” that they had to extend the holiday shutdown and retool the plant for a “significant increase in production,” and that they are “buying to that level of volume today” while remaining conservative on guidance.